Tarceva - Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer
Key Data:
Drug (brand/generic)
Tarceva (erlotinib)
Company/licensee
OSI Pharmaceuticals, Genetech, Roche
Therapy class
Anti-neoplastic agent
Product description
EGFR-tyrosine kinase inhibitor
Current indication
NSCLC
Market sector
Oncology
Development status
Approved in US and Europe
